SCIENTIFIC JOURNAL of the Hungarian Society of Cardiology

A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors

█ Review

DOI: 10.26430/CHUNGARICA.2023.53.4.337

Authors:
Eszter Dalma Pálinkás1,2,3, Róbert Sepp2, Iacopo Olivotto4, 5
1Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary
2Division of Non-Invasive Cardiology, Department of Internal Medicine,
Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary; Member
of the European Reference Network for rare, low prevalence, or complex diseases of the Heart (ERN GUARD Heart)
3Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy
4Cardiology Unit, IRCSS Meyer Children’s Hospital, Florence, Italy
5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

Summary

In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors reduces heart muscle hypercontractility, the core molecular defect of the disease, by selectively inhibiting cardiac beta-myosin. Based on the results obtained with the first two agents developed to date, mavacamten and aficamten, their use is safe and is associated with rapid and unprecedented improvement in quality of life and functional capacity in patients with left ventricular outflow tract obstruction, comparable to an optimal surgical result. This review provides an overview of the latest and most important studies that led to the approval of mavacamten by the U.S. Food and Drug Administration, and the clinical development of aficamten.

ISSUE: CARDIOLOGIA HUNGARICA | 2023 | VOLUME 53, ISSUE 4

click here to read the full article

click here to read the pdf

Watch the video summary